|Grant Number:||5R01CA143167-03 Interpret this number|
|Primary Investigator:||Hill, Dana|
|Organization:||Children'S Research Institute|
|Project Title:||Dicer1 and the Pleuropulmonary Blastoma Family Cancer Syndrome|
DESCRIPTION (provided by applicant): Studies of inherited cancer syndromes have provided unique opportunities to uncover and explain important cellular pathways. Pleuropulmonary blastoma (PPB) is a rare lung sarcoma that arises during fetal lung development and affects children under 6 years of age. In approximately 20% of cases, PPB appears to develop as the result of inherited cancer susceptibility. We have recently demonstrated germline loss of function DICER1 mutations in familial PPB. We hypothesize that inactivation of the wild-type DICER1 allele leads to tumor formation through dysregulation of genes controlled by miRNAs. Three highly integrated aims are proposed to further define the role DICER1 plays in PPB. In Aim 1, we will define the heritability of PPB and further characterize the PPB tumor predisposition syndrome by systematically collecting comprehensive personal medical histories from extended family members from 100 PPB families. In Aim 2 we will determine DICER1's role in PPB predisposition performing DICER1 mutation analysis in 100 PPB children. For each proband with a DICER1 mutation, we will test parents, siblings, grandparents and more distantly related members for the presence of family-specific mutations. We will explore candidate genes in cases lacking DICER1 mutations. These experiments will shed light on the genetic heterogeneity of PPB and will allow us to measure the penetrance and expressivity of DICER1 mutations. In Aim 3 we will determine DICER1's role in PPB initiation and evaluate potential mechanisms of oncogenesis. We will use immunohistochemistry to evaluate DICER1 expression in both tumor-associated epithelial and mesenchymal components and to guide subsequent somatic mutation studies of DICER1. Conceptually, this tumor may represent a naturally-occurring model of mesenchymal cell dysregulation. Preliminary data suggests that loss of DICER1 (and mature miRNAs) may occur primarily in the non-neoplastic epithelial component of the tumor leading to dysregulation of "tumor promoting factor(s)" that stimulate proliferation of the mesenchyme and predisposes the mesenchyme to sarcomatous transformation. The investigation of dysregulation in the context of malignancy may add to our knowledge base of epithelial-mesenchymal interactions in normal and abnormal lung development. The work proposed in this application will help test and refine this hypothesis and build the foundation for future mechanistic studies. A better understanding of this syndrome is essential to the development of clinical criteria for identifying these families and for guiding their medical care. Intensified radiologic screening examinations could be directed toward at-risk family members, leading to earlier detection of PPB in its purely cystic stage when the disease is more readily cured. In addition, study of families that show predisposition to PPB represent a unique opportunity to learn about the cellular processes in the borderland between development and neoplasia and to study how tissue-specific loss of DICER1 (and the miRNAs it regulates) manifests in human disease. PUBLIC HEALTH RELEVANCE: This work will shed light on the role genetics plays in a new pediatric tumor syndrome and could ultimately lead to new strategies to the detection and treatment of PPB and related tumors such as rhabdomyosarcoma and Wilms tumor.
Nasal chondromesenchymal hamartomas arise secondary to germline and somatic mutations of DICER1 in the pleuropulmonary blastoma tumor predisposition disorder.
Authors: Stewart DR, Messinger Y, Williams GM, Yang J, Field A, Schultz KA, Harney LA, Doros LA, Dehner LP, Hill DA
Source: Hum Genet, 2014 Aug 14;null, p. null.
EPub date: 2014 Aug 14.
Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences.
Authors: Pugh TJ, Yu W, Yang J, Field AL, Ambrogio L, Carter SL, Cibulskis K, Giannikopoulos P, Kiezun A, Kim J, McKenna A, Nickerson E, Getz G, Hoffher S, Messinger YH, Dehner LP, Roberts CW, Rodriguez-Galindo C, Williams GM, Rossi CT, Meyerson M, Hill DA
Source: Oncogene, 2014 Jun 9;0, p. null.
EPub date: 2014 Jun 9.
Judicious DICER1 testing and surveillance imaging facilitates early diagnosis and cure of pleuropulmonary blastoma.
Authors: Schultz KA, Harris A, Williams GM, Baldinger S, Doros L, Valusek P, Frazier AL, Dehner LP, Messinger Y, Hill DA
Source: Pediatr Blood Cancer, 2014 Sep;61(9), p. 1695-7.
EPub date: 2014 May 13.
DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma.
Authors: Doros LA, Rossi CT, Yang J, Field A, Williams GM, Messinger Y, Cajaiba MM, Perlman EJ, A Schultz K, Cathro HP, Legallo RD, LaFortune KA, Chikwava KR, Faria P, Geller JI, Dome JS, Mullen EA, Gratias EJ, Dehner LP, Hill DA
Source: Mod Pathol, 2014 Sep;27(9), p. 1267-80.
EPub date: 2014 Jan 31.
DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome.
Authors: Doros L, Yang J, Dehner L, Rossi CT, Skiver K, Jarzembowski JA, Messinger Y, Schultz KA, Williams G, André N, Hill DA
Source: Pediatr Blood Cancer, 2012 Sep;59(3), p. 558-60.
EPub date: 2011 Dec 16.
Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry.
Authors: Schultz KA, Pacheco MC, Yang J, Williams GM, Messinger Y, Hill DA, Dehner LP, Priest JR
Source: Gynecol Oncol, 2011 Aug;122(2), p. 246-50.
EPub date: 2011 Apr 17.
DICER1 mutations in familial pleuropulmonary blastoma.
Authors: Hill DA, Ivanovich J, Priest JR, Gurnett CA, Dehner LP, Desruisseau D, Jarzembowski JA, Wikenheiser-Brokamp KA, Suarez BK, Whelan AJ, Williams G, Bracamontes D, Messinger Y, Goodfellow PJ
Source: Science, 2009 Aug 21;325(5943), p. 965.
EPub date: 2009 Jun 25.